Эрадикационная терапия Helicobacter pylori: современные тенденции

1. Warren JR, Marshal B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273–5.
2. Kuipers EJ. Helicobacter pylori, MALT lymphoma and gastric cancer. J Chemther 1999; 11 (20): 25–8.
3. Megraud F, Coenen S, Versporten A et al. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008–2009. Ther Adv Gastroenterol 2012; 5 (2): 103–9.
4. Aqudo S, Perez-Perez G, Lopez-Brea M. High prevalence of clarithromycin resistance Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 2010; 48 (10): 3703–7.
5. Tong JL, Ran ZH, Shen J et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155–68.
6. Malfertheiner P, Megraud F, O’Morain C at al. Management of Helicobacter pylori infection – Maastricht IV / Florence consensus report. Gut 2012; 61: 646–64.
7. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012; 1: 87–9.
8. Szajewska H еt al. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol & Therapeutics 2010; 32 (9): 1069–79.
9. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
10. Cremonini F, Di Caro S, Covino M et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
11. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
12. Duman DG, Bor S, Ozütemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
13. Song MJ, Park DI, Park JH et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15 (3): 206–13.
14. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
15. Gotteland M, Poliak L, Cruchet S, Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr 2005; 94: 1747–51.
16. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterol 1994; 107 (6): 1671–4.
17. Falsafi T, Valizadeh N, Najafi M et al. Culture of Helicobacter pylori from stool samples in children. Can J Microbiol 2007; 53 (3): 411–6.
18. Topping DI, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiological Rev 2001; 81 (3): 1031–64.

Н.Н.Дехнич

Кафедра факультетской терапии ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ